Health

AstraZeneca Confirms Strong Vaccine Protection After US Rift

Published

4 years ago

March 25, 2021

AstraZeneca insists that its COVID-19 vaccine is strongly effective even after counting additional illnesses in its U.S. study, the latest in an extraordinary public dispute with American officials.

In a late-night news release Wednesday, the drugmaker said it had analyzed more data from that study and concluded the vaccine is 76% effective in preventing symptomatic COVID-19, instead of the 79% it had reported earlier in the week.

Just a day earlier, an independent panel that oversees the study had accused AstraZeneca of cherry-picking data to tout the protection offered by its vaccine.

The panel, in a harsh letter to the company and to U.S. health leaders, said the company had left out some COVID-19 cases that occurred in the study, a move that could erode trust in the science.

Some experts said the new data provided by AstraZeneca was “reassuring” and that the information was likely solid enough for U.S. regulators to authorize the vaccine.

“AstraZeneca may have just been too hasty in submitting the earlier, incomplete interim analysis rather than waiting to analyze and submit the full dataset,” said Julian Tang, a virologist at the University of Leicester who was not connected to the research.

He said the updated details didn’t look substantially different from what was published earlier this week.

Data disputes during ongoing studies typically remain confidential but in an unusual step, the National Institutes of Health publicly called on AstraZeneca to fix the discrepancy.

AstraZeneca had been counting on findings from a predominantly U.S. study of 32,000 people to help rebuild confidence in a vaccine that, despite being widely used in Britain, Europe and other countries, has had a troubled rollout.

Previous studies have turned up inconsistent data about its effectiveness, and then last week a scare about blood clots had some countries temporarily pausing inoculations.

Most have since restarted after the European Medicines Agency said the vaccine doesn’t increase the overall incidence of blood clots.

But it could not rule out a connection to some rare blood clots and issued new advice for monitoring those who get vaccinated.

Now the question is whether the company’s newest calculations can end the tension. Even before the latest spat, experts had expressed concern that missteps in the vaccine’s rollout could undermine confidence in the shot, which is crucial to global efforts to end the coronavirus pandemic since it is cheap, easy to store and a pillar of the COVAX initiative aimed at bringing vaccines to low- and middle-income countries.

Earlier Wednesday, Dr. Anthony Fauci, the top U.S. infectious disease expert, told reporters he hoped that when all the data was publicly vetted by federal regulators, it would dispel any hesitancy caused by the spat. He predicted it would “turn out to be a good vaccine.”

AstraZeneca’s newest calculations were based on 190 COVID-19 cases that occurred during the study, 49 more than it had included earlier in the week.

The vaccine appears especially protective against the worst outcomes, with no severe illnesses or hospitalizations among vaccinated study volunteers compared to eight severe cases among those given dummy shots, the company said. It didn’t provide a breakdown of the rest of the cases.

Some European authorities have questioned how protective the vaccine is in older adults. In the U.S. study, it was 85% effective in volunteers 65 and older, the company said. The study didn’t turn up safety concerns.

The updated information “confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over,” AstraZeneca research chief Mene Pangalos said in a statement. He said the company looks forward to “the rollout of millions of doses across America.”

The study hasn’t ended, so additional COVID-19 cases can still accrue. AstraZeneca cautioned that 14 additional possible cases already are being examined and that could lead to further changes in the data.

The company intends to seek Food and Drug Administration clearance of the vaccine within a few weeks. The FDA will publicly debate all the evidence with its outside advisers before making a decision.

Stephen Evans, a vaccines expert at the London School of Hygiene and Tropical Medicine, said it was difficult to understand why the dispute between AstraZeneca and U.S. officials spilled into the public.

“Given the details given here, it seems an unnecessary action to have raised concerns in public,” he said. “Results fluctuate as data accumulate … what counts will be the FDA assessment and that will be done based on scrutiny of the full data and not press releases.”

He said any vaccine with an efficacy rate higher than 60% is useful.

He said it was unclear why there was “a breakdown in relations” between AstraZeneca and the independent U.S. data experts monitoring the trial and worried that could undermine confidence in the vaccine.

“This vaccine is so important for global health, and the disputes do not promote global health,” he said.

“At least in the short term, (this) will undermine confidence both in the U.S. and more importantly in the rest of the world.”

(AP)

Health

LASG FLags Off Polio Outbreak Response Campaign

Published

6 months ago

January 20, 2025

Editor

The Lagos State Government, through the Lagos State Primary Health Care Board, has launched the 2025 Polio Outbreak Response Campaign, reaffirming its commitment to eradicating polio and safeguarding the health of its children.

The ceremony, held at the Simpson Primary Healthcare Centre, was led by the First Lady of Lagos State, Dr. (Mrs.) Claudiana Ibijoke Sanwo-Olu, represented by Mrs. Widad Jumoke Mustafa, a member of the Committee of Wives of Lagos State Officials (COWLSO).

In her address, the First Lady emphasised the state government’s proactive measures to keep Lagos polio-free, highlighting the critical importance of the campaign in preventing the debilitating effects of poliomyelitis, which can result in paralysis or death.

The First Lady also called on parents, community leaders, and stakeholders to support the campaign by ensuring eligible children are vaccinated.

Targeting children aged 0-59 months, vaccination teams will administer the Oral Polio Vaccine (OPV) to prevent virus transmission.

Dr. Kemi Ogunyemi, the Special Adviser on Health, expressed gratitude to Lagosians for their continued cooperation in the fight against polio. While appreciating all healthcare workers and partners for their services, Mrs. Ogunyemi encouraged parents to present their children and wards for the exercise.

Also speaking, the Chairman of Lagos Mainland Local Government, Mrs. Omolola Rashidat Essien opined that Immunization is key in ensuring that children are kept safe from polio and other vaccine preventable diseases.

Dr. Abimbola Bowale, the Supervising Permanent Secretary, Lagos State Primary Health Care Board, who also spoke at the event, underscored the life-saving importance of immunization.

“All children aged 0-59 months need multiple doses of the polio vaccine to ensure full protection. Any child missed represents a potential risk for the poliovirus to spread. The vaccine is safe, effective, and crucial in keeping our communities polio-free,” he stated.

Dr. Bowale also outlined several strategies to ensure the success of the campaign, including fixed post teams stationed at primary healthcare centres and public health facilities, house-to-house visits, and a transit strategy to reach special locations such as places of worship, schools, motor parks, and other public venues.

The event concluded with Dr. (Mrs.) Claudiana Ibijoke Sanwo-Olu officially launched the campaign, marking a renewed effort to maintain Lagos State’s polio-free status.

Headline

Lagos Cholera Cases Rise To 421

Published

1 year ago

June 22, 2024

Editor

The Lagos state suspected cholera cases have risen to 421.

The Commissioner for Health, Akin Abayomi disclosed this on his Instagram handle @profakinabayomi on Saturday.

“As of June 20, 2024, an additional four suspected cholera cases have been reported, as illustrated in the accompanying graph,” he wrote.

He noted that the Emergency Operations Centre in collaboration with all relevant partners is actively engaged in contact tracing, community-based surveillance, awareness campaigns, sample testing, and ensuring that confirmed cholera cases receive appropriate medical treatment.

On Friday, the commissioner confirmed 35 cases out of the 417 suspected cases and 24 deaths across 20 Local Government Areas in the state.

The cases were reported from Agege, Badagry, Ikeja, Mushin, Ajeromi-Ifelofun, Epe, Ikorodu, Ojo, Alimosho, and Eti-Osa.

Others were Kosofe, Oshodi-Isolo, Amuwo-Odofin, Ibeju-Lekki, Lagos Island, Shomolu, Apapa, Ifako-Ijaiye, Lagos mainland, and Surulere.

Cholera is a food and water-borne disease caused by ingesting the bacteria— Vibrio cholerae — in contaminated water and food. Cholera can cause severe acute watery diarrhoea, and the severe forms of the disease can kill within hours if left untreated.

In Nigeria, cholera is an endemic and seasonal disease, occurring annually mostly during the rainy season and more frequently in areas with poor sanitation.

The World Health Organisation on Thursday announced a spike in cholera in several regions of the world, with almost 195,000 cases and over 1,900 deaths reported in 24 countries since the start of 2024.

WHO said the Eastern Mediterranean Region reported the highest number of cases, followed by the African Region, the Region of the Americas, the Southeast Asia Region, and the European Region.

The global health body, however, noted that there are no reported cases in the Western Region, according to its bulletin released on Wednesday.

It said it exhausted its global stockpile of Oral Cholera Vaccines by March but was able to exceed “the emergency target of five million doses in early June for the first time in 2024.”

Health

AUTISM: What You Need To Know

Published

1 year ago

April 6, 2024

Editor

By Silver Yeibake

Autism, commonly known as Autism Spectrum Disorder (ASD), is a neurodevelopmental disorder that affects communication, social interaction, and behavior. Autism is referred to as a spectrum condition since it can manifest in a variety of symptoms and abilities. While the actual cause of autism is unknown, evidence suggests that genetic and environmental factors interact to influence its development.

The risk factors include a sibling with autism, advanced age of parents, exposure to certain air pollutants and pesticides before birth, extreme prematurity, mothers with diabetes, immune system disorders or obesity, any difficulty with delivery leading to deprivation of oxygen to the baby’s brain, fever during pregnancy, lack of certain vitamins minerals during pregnancy, and certain genetic conditions, such as Down, fragile X, and Rett syndromes.

“Risk factors can not on their own cause a disease. However, they can increase the likelihood of that disease in a person.”

It is important to know that contrary to trending claims online, there is no scientific or medical evidence that vaccines or consumption of sugar are risk factors for autism.

Autism is defined by difficulties in social interaction and communication. Individuals with autism may struggle to grasp social cues, maintain eye contact, and engage in typical back-and-forth conversations. Some people may also engage in meaningless, repetitive actions, such as hand-flapping or rocking, and have strong interests in specific areas.

It is essential to remember that autism is a lifelong diagnosis, but with early intervention and adequate care, people with autism can live fulfilling lives.
Autism treatment frequently includes behavioral therapy, speech therapy, occupational therapy, and social skills training. Each individual with autism is unique, thus interventions should be tailored to meet their personal needs and strengths.

In spite of the difficulties that autism can cause, many people with autism possess unique talents and abilities. Some people may succeed in fields such as music, art, mathematics, or programming, thus it is important for society to acknowledge and honor the qualities and achievements of people with autism.

In summary, autism is a complicated and diverse disorder that affects individuals in various ways. By raising autism knowledge, understanding, and acceptance, we can build a more inclusive society in which people with autism can thrive and attain their full potential.

Dr. Yeibake, Weriwoyingipre Silver.
Senior Registrar,
Faculty Of Pediatrics,
WACP